Budipine

Budipine
	File:Budipine.svg
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	N04BX03 (WHO) ;
Identifiers
	IUPAC name 1-tert-butyl-4,4-diphenylpiperidine;
CAS Number	57982-78-2 ;
PubChem CID	68778;
ChemSpider	62021 ;
UNII	L9026OPI2Z;
KEGG	D07306 ;
ChEMBL	ChEMBL334491 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H27N
Molar mass	293.446 g/mol
3D model (JSmol)	Interactive image;
	SMILES c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3;
	InChI InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 ; Key:QIHLUZAFSSMXHQ-UHFFFAOYSA-N ;
(verify)

Budipine is an antiparkinson agent.

Its mechanism of action is not well characterized.^[2] It is believed to be an NMDA receptor antagonist,^[3] however, promoting the synthesis of dopamine.^[4]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.^[5]

References

↑ Martndale: The Complete Drug Reference, 35th Ed.
↑ Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
↑ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
↑ "umm.edu".
↑ Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.

Template:Antiparkinson

Template:Nervous-system-drug-stub

[1] Martndale: The Complete Drug Reference, 35th Ed.

[pmid16784759-2] Reichmann H (October 2006). "Budipine in Parkinson's tremor". J. Neurol. Sci. 248 (1–2): 53–5. doi:10.1016/j.jns.2006.05.039. PMID 16784759.

[3] J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048

[url-4] "umm.edu".

[pmid12020263-5] Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.

[1]

[2]

[3]

[4]

[5]

Budipine

See also

References

Navigation menu